Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Review Djibouti .
Press releases published on October 20, 2025
NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards
EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American’s continued listing standards. As previously disclosed, …
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat …
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced that, on October 20, 2025, …
Constellation Software Inc. Announces Release Date for Third Quarter Results
TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it intends to release its third quarter results on November 7, 2025. The Company’s quarterly results will be disseminated via press release and made available …
Topicus.com Inc. Announces Release Date for Third Quarter Results
TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) announced today it intends to release its third quarter results on November 4, 2025. The Company’s quarterly results will be disseminated via press release and made available on the …
DIH Announces Fiscal 2025 Fourth Quarter and Fiscal Year End Financial Results
NORWELL, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. (“DIH” or the “Company”) (NASDAQ:DHAI), a global provider of advanced robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to …
No Limits and Automae announce a strategic alliance to accelerate automation for SMEs in France and Switzerland
Geneva, Switzerland, Oct. 20, 2025 (GLOBE NEWSWIRE) -- No Limits, an ecosystem for business enablement and executive coaching, announces a strategic partnership with Automae, a no‑code automation consultancy founded by Théo Jim. The alliance combines …
NowVertical to feature in Fireside Chat at the Planet MicroCap Showcase: TORONTO on Wednesday, October 22, 2025
Fireside Chat with Stifel Financial Corp. will be hosted at 2:00PM EDT Wednesday, October 22, 2025 in partnership with MicroCapClub 1x1 Meetings scheduled on Thursday, October 23, 2025 TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- NowVertical Group Inc. ( …
3 E Network Technology Group Limited Announces Closing of US$1.5 Million Convertible Promissory Note Offering
HONG KONG, Oct. 20, 2025 (GLOBE NEWSWIRE) -- 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3e Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider, today announced the closing of …
Bio Usawa Announces Approval of BioUcenta™ by the Rwandan FDA
KIGALI, Rwanda and SAN FRANCISCO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- The Rwanda Food and Drugs Authority has granted market approval for Bio Usawa Biotechnology Ltd.’s (Bio Usawa) BioUcenta™, a biosimilar of Lucentis® (ranibizumab) for the treatment of …
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue®, a biosimilar to Herceptin® (trastuzumab) Tuznue® received European Commission (EC) marketing authorization in September 2024 Partnership brings …
Commerce to Announce Third Quarter 2025 Financial Results on November 6, 2025
AUSTIN, Texas, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Commerce.com, Inc. (Nasdaq: CMRC) (formerly BigCommerce Holdings, Inc.), a provider of an open, intelligent ecosystem of technology solutions that empower businesses to unlock data potential and deliver …
Onco360® Has Been Selected as a Specialty Pharmacy Partner for PHYRAGO™ (dasatinib)
LOUISVILLE, Ky., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Cycle Pharmaceuticals Ltd. for Phyrago™ (dasatinib) tablets. Phyrago is a kinase inhibitor …
CLEAR and Wellstar Health System Modernize the Patient Experience Using CLEAR1’s Digital Check-In
NEW YORK and ATLANTA, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CLEAR (NYSE: YOU), the secure identity company, and Wellstar Health System (“Wellstar”), are dramatically improving the patient experience and saving hundreds of staff hours through a partnership that …
Cycurion, Inc. Announces Nasdaq Delisting Determination Letter
MCLEAN, Va., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion” or the “Company”), a leading cybersecurity solutions provider, announced today that it received a Delisting Determination Letter from the staff of Nasdaq Listing …
Lirum Therapeutics Announces FDA “Study May Proceed” Letter Enabling Inclusion of LX-101 in the RAPID Platform Clinical Trial for Ewing Sarcoma and Desmoplastic Small Round Cell Tumor
New York, NY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that the U.S. Food and Drug Administration (FDA) …
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the …
La FDA autorise le système d’implant de pied et de cheville SINAPTIC® de SINTX Technologies
Fabriqué aux États-Unis et désormais approuvé par la FDA, ce système d’implant conçu par SINTX s’ouvre les portes d’un marché américain valorisé à plusieurs milliards de dollars SALT LAKE CITY, Utah, 20 oct. 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc …
SINTX Technologies מקבלת אישור FDA לטכנולוגיית השתלת כף רגל וקרסול SINAPTIC®
ה-FDA אישר ומערכת שתלים מתוצרת ארה"ב- ממצבת את SINTX בכניסה לשוק האמריקני של מיליארד דולר סולט לייק סיטי, יוטה, Oct. 20, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (נאסד"ק: SINT) ("SINTX" או "החברה"), חדשנית קרמיקה מתקדמת המתמחה ביישומים ביו-רפואיים …
SINTX Technologies erhält FDA-Zulassung für SINAPTIC® Fuß- und Sprunggelenk-Implantatsystem
Das von der FDA zugelassene und in den USA hergestellte Implantatsystem positioniert SINTX für den Eintritt in den milliardenschweren US-Markt SALT LAKE CITY, Utah, Oct. 20, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) („SINTX“ oder das …